Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

499

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

January 13, 2025

Study Completion Date

December 31, 2027

Conditions
Advanced CancerAngiosarcomaColorectal Cancer Without Liver MetastasesEndometrial CancerFibrolamellar CarcinomaNon-small-cell Lung CancerOvarian CancerProstate Cancer
Interventions
DRUG

Botensilimab

An Fc-engineered anti-CTLA-4 monoclonal antibody

DRUG

Balstilimab

A fully human monoclonal anti-PD-1 antibody

Trial Locations (18)

10029

Icahn School of Medicine at Mount Sinai, New York

10032

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

33136

University of Miami Sylvester Comprehensive Cancer Center, Miami

77030

MD Anderson Cancer Center, Houston

78229

The University of Texas Health Science Center at San Antonio, San Antonio

80045

University of Colorado, Aurora

85258

HonorHealth Research Institute, Scottsdale

90025

The Angeles Clinic & Research Institute, a Cedars-Sinai Affiliate, Los Angeles

90033

University of Southern California Norris Comprehensive Cancer Center, Los Angeles

90095

UCLA Santa Monica Hematology Oncology, Los Angeles

90404

Saint John's Cancer Institute, Santa Monica

91010

City of Hope Comprehensive Cancer Center, Duarte

97213

Providence Portland Cancer Center, Portland

06520

Yale Cancer Center, New Haven

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

SW3 6JJ

Royal Marsden Hospital NHS Foundation Trust, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Agenus Inc.

INDUSTRY

NCT03860272 - Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | Biotech Hunter | Biotech Hunter